Gustav Gaudernack

Gustav Gaudernack's AcademicInfluence.com Rankings

Gustav Gaudernack

Biology

#5941

World Rank

#8548

Historical Rank

Immunology

#448

World Rank

#465

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Gustav Gaudernack Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Gustav Gaudernack is a scientist working in the development of cancer vaccines and cancer immunotherapy. He has developed various strategies in immunological treatment of cancer. He is involved in several ongoing cellular and immuno-gene therapeutic clinical trials and his research group has put major efforts into the development of various T cell-based immunotherapeutic strategies.

(See a Problem?)

Gustav Gaudernack's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study (2001) (873)
Therapeutic vaccines for cancer: an overview of clinical trials (2014) (610)
Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. (1999) (432)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study (2006) (280)
HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation--a fast and reliable technique. (2008) (277)
Intradermal ras peptide vaccination with granulocyte‐macrophage colony‐stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma (2001) (269)
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer (2001) (258)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer (2006) (235)
In vitro differentiation of human monocytes. Differences in monocyte phenotypes induced by cultivation on glass or on collagen (1982) (234)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma (2013) (215)
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation (1995) (206)
Different genetic pathways to proximal and distal colorectal cancer influenced by sex‐related factors (1997) (195)
CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. (1990) (193)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA (2006) (189)
Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules (1995) (175)
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21‐ras (12VAL) peptide vaccination of a patient, recognize 12VAL‐dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation (1997) (161)
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial (2011) (155)
Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras (2011) (151)
K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. (1994) (146)
mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). (2002) (144)
Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. (1999) (143)
Isolation of pure functionally active CD8+ T cells. Positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres. (1986) (141)
Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines (2013) (133)
Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma (2014) (119)
Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients (2011) (117)
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study (1996) (115)
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients (2005) (102)
Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues (2006) (102)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes (2011) (96)
Formation of biocompatible nanocapsules with emulsion core and pegylated shell by polyelectrolyte multilayer adsorption. (2010) (95)
DEPLETION OF T LYMPHOCYTES FROM HUMAN BONE MARROW: Use of Magnetic Monosized Polymer Microspheres Coated with T‐Lymphocyte‐Specific Monoclonal Antibodies (1987) (93)
p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp) (2007) (93)
Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells. (1992) (91)
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells (2006) (90)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model (2015) (87)
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001 (2012) (86)
Direct immunomagnetic quantification of lymphocyte subsets in blood. (1988) (80)
Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61). (1992) (79)
NY‐ESO‐1 protein expression and humoral immune responses in prostate cancer (2004) (75)
Induction of Various HLA Class II Molecules in a Human Colonic Adenocarcinoma Cell Line (1987) (73)
A TCR-based Chimeric Antigen Receptor (2017) (72)
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention (2020) (71)
Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display (2004) (70)
A Protocol for Generation of Clinical Grade mRNA‐Transfected Monocyte‐Derived Dendritic Cells for Cancer Vaccines (2003) (68)
A TGFβRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells (2001) (67)
T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. (1992) (67)
Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cells (1993) (65)
A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines (2007) (63)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer (2017) (62)
T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restriction (1993) (62)
Stress Causes Reduced Natural Killer Activity in Mice (1983) (61)
K-ras mutations and prognosis in large-bowel carcinomas. (1997) (61)
Myeloid differentiation of purified CD34+ cells after stimulation with recombinant human granulocyte-monocyte colony-stimulating factor (CSF), granulocyte-CSF, monocyte-CSF, and interleukin-3. (1991) (59)
Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. (1999) (59)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells (2007) (59)
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination (2005) (58)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth (2017) (56)
Transiently redirected T cells for adoptive transfer. (2011) (54)
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. (2016) (53)
Improving the efficacy of cancer immunotherapy. (2009) (50)
Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide. (1990) (49)
Independent prognostic significance of HER‐2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy (2002) (49)
Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction. (1998) (48)
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination (2009) (48)
A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. (2001) (47)
Dendritic Cells and Monocytes as Accessory Cells in T‐Cell Responses in Man (1985) (46)
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides (2011) (46)
A K‐ras 13GLY → ASP mutation is recognized by HLA‐DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? (1994) (46)
NK cells specifically TCR-dressed to kill cancer cells (2019) (45)
RAPID IMMUNOMAGNETIC PHENOTYPING OF CELLS (1989) (45)
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination (2015) (40)
Dendritic Cells and Monocytes as Accessory Cells in T‐Cell Responses in Man (1985) (40)
Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM‐CSF as adjuvant (2001) (39)
Immunization with the Light Chain and the VL Domain of the Isologous Myeloma Protein 315 Inhibits Growth of Mouse Plasmacytoma MOPC315 (1980) (38)
K-ras mutations and HLA-DR expression in large bowel adenomas. (1996) (37)
Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. (2010) (37)
HLA-DQ antigens and DQ beta amino acid 57 of Japanese patients with insulin-dependent diabetes mellitus: detection of a DRw8DQw8 haplotype. (1989) (36)
Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer (1998) (36)
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. (1996) (35)
The TCR-binding region of the HLA class I alpha2 domain signals rapid Fas-independent cell death: a direct pathway for T cell-mediated killing of target cells? (1998) (35)
Polyelectrolyte multilayer capsules with quantum dots for biomedical applications. (2012) (35)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells (2016) (33)
Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells (1996) (33)
T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA (1994) (33)
Expression of Activation Markers on CD4+ and CD8+ Cells from Synovial Fluid, Synovial Tissue, and Peripheral Blood of Patients with Inflammatory Arthritides (1989) (32)
Localization of receptors and early events of phagocytosis in the macrophage. (1975) (31)
Thromboplastin (tissue factor) in plasma membranes of human monocytes. (1985) (31)
Induction of Tissue Factor Synthesis in Human Umbilical Vein Endothelial Cells Involves Protein Kinase C (1992) (30)
Characterization of an HLA-DQ2-specific monoclonal antibody. Influence of amino acid substitutions in DQ beta 1*0202. (1995) (30)
In vitro replication of hiv-1 in naturally infected cd4+t cells is inhibited by rifnα2 and by a soluble factor secreted by activated cd8+ t cells, but not by rifnβ, rifnγ, or recombinant tumor necrosis factor-α (1991) (30)
Culture characterization of differentiated high endothelial venule cells from human tonsils. (1999) (30)
Microcytotoxic HLA typing of cells directly isolated from blood by means of antibody-coated microspheres. (1987) (29)
A new method for isolation of reticulocytes: positive selection of human reticulocytes by immunomagnetic separation. (1990) (28)
Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia (2005) (28)
Humoral immunity and output of first-stage larvae of Elaphostrongylus rangiferi (Nematoda, Metastrongyloidea) by infected reindeer, Rangifer tarandus tarandus (1984) (28)
Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer (2000) (28)
Identification of Cancer Stem-like Side Population Cells in Ovarian Cancer Cell Line OVCAR-3 (2009) (27)
Resolving the evolutionary paradox of genetic instability: a cost–benefit analysis of DNA repair in changing environments (2004) (27)
Positive selection of activated T cells of the T8 (CD8) sub-type by immunomagnetic separation. (2008) (26)
HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes (2002) (26)
Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. (2009) (26)
Transplantation and gene transfer of the human glucocerebrosidase gene into immunoselected primate CD34+Thy-1+ cells. (1996) (25)
Isolation of pure and functionally active T4 and T8 cells by positive selection with antibody-coated monosized magnetic microspheres. (1987) (25)
CD8+T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (GLY13→ASP), are cytotoxic towards a carcinoma cell line harbouring the same mutation (1995) (25)
Staphylococcal exotoxin superantigens induce human immunodeficiency virus type 1 expression in naturally infected CD4+ T cells (1992) (25)
Direct identification of all oncogenic mutants in KRAS exon 1 by cycling temperature capillary electrophoresis (2003) (24)
Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens (1989) (23)
Mutation detection in KRAS Exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries. (2002) (23)
Reliable isolation of human immunodeficiency virus from cultures of naturally infected CD4+ T cells. (1989) (23)
T lymphocyte clones recognizing an HLA-DQw3.2-associated epitope involving residue 57 on the DQ beta chain. (1988) (23)
Impaired in vitro survival of monocytes from patients with HIV infection (1990) (23)
Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma (2005) (22)
T- and B-cell-independent activation of syngeneic macrophages by murine sarcoma cells. (1980) (22)
Activation of Resting, Pure CD4+, and CD8+ Cells via CD3 (1987) (22)
Population Screening of Single-Nucleotide Polymorphisms Exemplified by Analysis of 8000 Alleles (2002) (22)
A Human Melanoma Cell Line, Recognized by Both HLA Class I and Class II Restricted T Cells, is Capable of Initiating both Primary and Secondary Immune Responses (1995) (22)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab (2013) (21)
Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif (2010) (21)
Production of BALB/c Anti‐Idiotypic Antibodies Against the BALB/c Myeloma Protein 315 Does Not Require an Intact Ligand‐Binding Site (1977) (21)
A Functional Study of Purified CD4+ and CD8+ Cells Isolated from Synovial Fluid of Patients with Rheumatoid Arthritis and Other Arthritides (1989) (21)
Role of the TCR binding region of the HLA class I alpha 2 domain in regulation of cell adhesion and proliferation. (1996) (21)
Development of a Clinical Grade Procedure for Generation of mRNA Transfected Dendritic Cells from Purified Frozen CD34+ Blood Progenitor Cells (2004) (20)
Antigen-specific T cell clones restricted by DR, DRw53 (MT), or DP (SB) Class II HLA molecules. Inhibition studies with monoclonal HLA-specific antibodies. (1984) (20)
Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations. (2001) (19)
Evaluation of denaturing conditions in analysis of DNA variants applied to multi-capillary electrophoresis instruments (2003) (19)
Requirements for Phytohaemagglutinin Activation of Resting Pure CD4+ and CD8+ T Cells (1988) (19)
Antibodies to and elevations of beta 2 microglobulin in the serum of ankylosing spondylitis patients. (1982) (19)
Role of Accessory Cells in the Activation of Pure T Cells via the T Cell Receptor‐CD3 Complex or with Phytohaemagglutinin (1988) (18)
Effect of UVA and PUVA on alloactivating and antigen-presenting capacity of human epidermal Langerhans cells. (1987) (18)
T cells recognizing an HLA-DQ αß heterodimer encoded in Cis by the DR4DQw4 haplotype and in Trans by DR4DQw8/DRw8DQw4 heterozygous cells (1991) (18)
POSITIVE SELECTION OF Tac‐ (CD25) POSITIVE CELLS FOLLOWING T‐CELL ACTIVATION: USE OF IMMUNOMAGNETIC SEPARATION AND IMPLICATIONS FOR T‐CELL CLONING (1989) (17)
Approach to analysis of single nucleotide polymorphisms by automated constant denaturant capillary electrophoresis. (2003) (17)
Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. (1988) (17)
Studies on the biosynthesis of factor VII (proconvertin). The mode of action of warfarin. (1971) (17)
Dendritic Cells Engineered to Express Defined Allo‐HLA Peptide Complexes Induce Antigen‐specific Cytotoxic T Cells Efficiently Killing Tumour Cells (2009) (17)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma (2012) (16)
Identification of Platelet Antigens by Monoclonal Antibodies Using Crossed Immunoelectrophoresis with Immunoblotting of the Monoclonal Antibody (1987) (16)
CDw78 — a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton (1997) (15)
Prospects for vaccine therapy for pancreatic cancer. (2006) (15)
A new method for isolation of reticulocytes: positive selection of human reticulocytes by immunomagnetic separation (1990) (15)
Identification, at the genomic level, of an HLA-DR restriction element for cloned antigen-specific T4 cells (1985) (15)
Mitogen‐Induced Interleukin 2 and Gamma Interferon Production by CD4+ and CD8+ Cells of Patients with Inflammatory Arthritides. A Comparison between Cells from Synovial Fluid and Peripheral Blood (1989) (14)
T‐Cell Recognition of HLA Class II Molecules Induced by Gamma‐Interferon on a Colonic Adenocarcinoma Cell Line (HT29) (1990) (14)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer (2020) (14)
Enriched Langerhans Cells Express More HLA‐DR Determinants Than Blood‐Derived Adherent Cells (Monocytes and Dendritic Cells) (1985) (14)
Allogenic induction of thromboplastin synthesis in monocytes and endothelial cells. Biphasic effect of cyclosporin A. (1989) (14)
Specificity of γδ Receptor‐Bearing Cytotoxic T Lymphocytes Isolated from Human Peripheral Blood (1989) (13)
Mutation Analysis of TP53 Exons 5–8 by Automated Constant Denaturant Capillary Electrophoresis (2001) (13)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy (2016) (13)
Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination (1997) (13)
HLA-DQw3.1 and DQw3.2 associated exon polymorphisms detected by oligonucleotide probes. (1988) (13)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity (2019) (13)
Monoclonal hybridoma antibodies to human amyloid related protein SAA. (1982) (13)
The PhastSystem equipment used for crossed immunoelectrophoresis combined with immunoblotting of coprecipitated monoclonal antibodies as studied with platelet membrane receptor proteins (1989) (13)
Relative efficiency of human Langerhans' cells and blood derived dendritic cells as antigen-presenting cells. (1985) (12)
In vitro replication of HIV-1 in naturally infected CD4+ T cells is inhibited by rIFN alpha 2 and by a soluble factor secreted by activated CD8+ T cells, but not by rIFN beta, rIFN gamma, or recombinant tumor necrosis factor-alpha. (1991) (12)
Identification of prostate cancer antigens by automated high-throughput filter immunoscreening. (2008) (12)
Positive selection of bone marrow-derived CD34 positive cells for possible stem cell transplantation. (1993) (12)
T cell-epithelium interactions in relation to gut immunity. (1988) (11)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial (2021) (11)
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential (2021) (11)
Ligand‐Induced Redistribution and Augmentation of Surface‐Bound Myeloma Protein on MOPC315 Plasmacytoma Cells (1977) (11)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy (2019) (11)
Combination of GM-CSF with antitumour vaccine strategies. (1999) (11)
Characterization of a monoclonal antibody recognizing a polymorphic epitope mainly on HLA-DPw2 and DPw4 molecules. (1989) (11)
Melting gel techniques in single nucleotide polymorphism and mutation detection: From theory to automation (2002) (10)
Synthesis of serum proteins by a clonal strain of rat hepatoma cells. (1973) (10)
In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines (2013) (10)
Early stage carcinoma of the uterine cervix. Effects of intracavitary radium treatment on lymphoid cells in blood and pelvic lymph nodes. (1986) (10)
mRNA transfection of DC in the immature or mature state: comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA. (2007) (10)
Generation and characterization of GP‐100 peptide‐specific NK‐T cell clones (1998) (10)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy (2020) (10)
Tissue thromboplastin generation in circulating mononuclear phagocytes and development of coagulation disorders during E. coli endotoxinaemia in pigs. (1985) (10)
The Role of the CD8‐Positive Subset of T Cells in Proliferative Responses to Soluble Antigens (1986) (9)
A simple and sensitive bioassay for the detection of IL-2 activity. (1988) (8)
Isolation of functionally active T cell receptor γδ-bearing lymphocytes from human peripheral blood (1989) (8)
A phase I/II study of telomerase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma. (2006) (8)
Immunomagnetic isolation of cells for serological BoLA typing. (2009) (8)
Binding of Ras Oncogene Peptides to Purified HLA‐DQ(αl*0102, ß1*0602) and ‐DR(α, ß1*0101) Molecules (1994) (8)
Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane. (2002) (7)
EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase. (2008) (7)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials (2022) (7)
Human granulopoiesis in vitro--medium-dependent growth regulation by a granulocyte-derived inhibitor. (1988) (7)
Epitopes on HLA-DQw3 Molecules Recognized by T-Lymphocyte Clones (1989) (7)
Characterization of a monoclonal antibody ITI‐Pl 1 directed against human platelet membrane glycoprotein IIb using extracts of whole platelets and platelet surface and intracellular membranes (1988) (7)
Characterization and epitope mapping of four HLA class II reactive mouse monoclonal antibodies using transfected L cells and human cells transfected with mutants of DQB1*0302. (1995) (7)
RG1, a new murine monoclonal antibody recognizing a "supertypic" determinant on HLA-A molecules. (1995) (6)
RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival (2007) (6)
Rapid identification of human B-lymphocytes and monocytes with rhodamine-labeled Brucella melitensis. (1981) (6)
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination (2019) (6)
Awareness and understanding of cancer immunotherapy in Europe (2014) (5)
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors (2021) (5)
Oncogene-derived peptides: a new class of tumor rejection antigens? (1993) (5)
Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix (1992) (5)
Ability of Pure Resting CD8+ Human T Cells to Respond to Alloantigen (1989) (5)
Influence on antibody recognition of amino acid substitutions in the cleft of HLA-DQ2 molecules. Suggestive evidence of peptide-dependent epitopes. (1995) (5)
Heterogeneity of T cells specific for a particular peptide/HLA-DQ complex. (1994) (5)
A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer (2005) (5)
Effects of endotoxins from Bacteroides intermedius and Escherichia coli on human monocytes in vitro. (2009) (5)
Immunological Studies on the Blood Coagulation Factor X and Its Warfarin-induced Precursor (1974) (5)
Analysis of the autoantibody repertoire in Burkitt’s lymphoma patients: frequent response against the transcription factor ATF-2 (2004) (5)
Mouse L Cells Expressing Human HLA-DR Antigens After Transfection with Class II Genes Do Not Stimulate Human T Lymphocytes (1984) (5)
A unique monoclonal antibody inhibits the second wave of platelet aggregation. (1982) (4)
Binding of ras oncogene peptides to purified HLA-DQ (alpha 1*0102, beta 1*0602) and -DR (alpha, beta 1*0101) molecules. (1994) (4)
Isolation of functionally active T-cell subsets by monoclonal antibodies conjugated to monodisperse magnetic microspheres (M-450) (1986) (4)
Human T Lymphocyte Clones: Influence of Culture Conditions and Optimization of Proliferative Assays (1989) (4)
Induction of Interleukin‐2 Production in CD4+ and CD8+ T‐Cell Subsets after Activation via CD3 and CD2 (1988) (4)
Analysis of infiltrating lymphocytes from fine needle aspiration biopsies in kidney transplant patients by a rapid and sensitive immunomagnetic method. (1989) (4)
Suppressive Effect of Monocytes in Vitro in Patients with Carcinoma of the Uterine Cervix (1986) (4)
Small megakaryocytes — an identification problem (1988) (3)
Dendritic cells transfected with allo-tumor mRNA as cancer vaccine in treatment of hormone resistant prostate cancer patients (2005) (3)
Immunological Typing of Acute Leukaemias by Rosetting with Immunomagnetic Beads: Comparison with Immunofluorescence Staining (1990) (3)
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination (2022) (3)
T cell responses against mutant ras: a basis for novel cancer vaccines. (1996) (3)
Phase I/II trial of vaccine therapy with tumor-RNA transfected dendritic cells in patients with advanced malignant melanoma (2005) (3)
“Built‐in” PD‐1 blocker to rescue NK‐92 activity from PD‐L1–mediated tumor escape mechanisms (2021) (3)
A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update. (2020) (3)
Immunotherapy of patients with pancreatic adenocarcinoma: Influence of adjuvants (2008) (2)
The Plasma Cell Differentiation Antigen PC.1 is Absent in CH3/Tif and Present in C3H/HeJ (1979) (2)
The Mild Inflammatory Response in Febrile Neutropenic Lymphoma Patients with Low Risk of Complications is More Pronounced in Patients Receiving Tobramycin Once Daily Compared with Three Times Daily (2011) (2)
Awareness and understanding of cancer immunotherapy in Europe. (2013) (2)
Cross-linking of a sequential epitope within the beta-chain of HLA-DR/DP molecules suppressing B lymphocyte growth and inducing homotypic cell aggregation. (1994) (2)
Expression of HLA class II molecules on human monocytes and dendritic cells (1984) (2)
Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras (1994) (2)
Tumour‐Host Interactions in Vivo (1983) (2)
T Cell Responses in Patients Vaccinated with Telomerase (hTERT)-mRNA Transfected Dendritic Cells. (2009) (1)
1154PTelomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial (2017) (1)
A Simple and Rapid Procedure for Purification of Human Dendritic Cells from Peripheral Blood (1984) (1)
Activation of mononuclear phagocyte functions by structurally different bacterial endotoxins. (1988) (1)
The Role of the CD8‐Positive Subset of T Cells in Proliferative Responses to Soluble Antigens (1986) (1)
Isolation of functionally active T cell receptor gamma delta-bearing lymphocytes from human peripheral blood. (1989) (1)
A TGFβRII frameshift mutation derived CTL epitope recognised by HLA-A2 restricted CD8+ T cells (2001) (1)
HLA class II profile of a human carcinoma cell line: Detection on genomic level and after exposure to γ-interferon (1987) (1)
Abstract 2235: Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin (2016) (1)
Abstract 3773: Tapping CD4 T cells for cancer immunotherapy (2017) (1)
Studies on PIVKA-X (1975) (1)
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor‐specific HLA variants (2022) (1)
T cells recognizing an HLA-DQ alpha beta heterodimer encoded in cis by the DR4DQw4 haplotype and in trans by DR4DQw8/DRw8DQw4 heterozygous cells. (1991) (1)
Effect of recombinant stem cell growth factors on immunomagnetically isolated CD34+ cells (1992) (1)
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy (2019) (1)
O.10. Immunoblotting of monoclonal antibodies after crossed immunoelectrophoresis (1987) (1)
Antigen-Specific T Cell Clones Restricted by DR, DQ, or DP Class II HLA Molecules (1984) (0)
Polypeptides which can elicit an immune response against the cancer (2001) (0)
Abstract 2306: Treatment with hTERT/survivin mRNA-loaded dendritic cells combined with autologousex vivoexpanded T cells improves progression free survival in stage IV melanoma patients when compared to dendritic cell vaccines alone (2016) (0)
Abstract 3146: T cell therapy targeting a neoantigen reducesin vivotumour growth (2015) (0)
A TCR-based Chimeric Antigen Receptor (2017) (0)
telomerase antigen peptides derived (1999) (0)
BY STRUCTURALLY DIFFERENT BACTERIAL ENDOTOXINS (1988) (0)
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma (2023) (0)
Her-2 expression is of independent prognostic significance in pNO prostate cancer undergoing curative radiotherapy (2001) (0)
Cancer Vaccines: From mutant ras to telomerase peptides* (1999) (0)
4PDA universal killer T-cell for adoptive cell therapy of cancer (2015) (0)
963 Clinical trial of a peptide based vaccine targeting telomerase in patients with inoperable pancreatic cancer (2003) (0)
HLA class II profile of a human carcinoma cell line: detection on genomic level and after exposure to gamma-interferon. (1987) (0)
A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response (2010) (0)
11PDTapping CD4 T cells for cancer immunotherapy (2016) (0)
Isolement de l'acide nucleique (1994) (0)
Efficient Generation of Tumor-Specific, Cytotoxic T Cells by Genetic Transfer of allo-MHC. (2007) (0)
Spacer design influences the in vivo efficacy of CD19-CAR redirected T cells (2014) (0)
HLA restriction fine-specificity and T-cell receptor usage of T cells recognizing DQ7. (1994) (0)
36PUV1 - A peptide-based, therapeutic cancer vaccine targeting the reverse transcriptase subunit of human telomerase (hTERT) (2016) (0)
Clinical experiences with therapeutic DC vaccines targeting autologous cancer stem cells in glioblastoma (2013) (0)
Specificity of gamma delta receptor-bearing cytotoxic T lymphocytes isolated from human peripheral blood. (1989) (0)
382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma (2021) (0)
Tumor--host interactions in vivo. II. Induction of NK-cell activity by intraperitoneal injection of murine sarcoma cells or tumor ascites fluid. (1983) (0)
Peptides and peptide fragments of therapeutically useful. (1992) (0)
Abstract B141: Combining the telomerase peptide cancer vaccine UV1 with CTLA-4 blockade in patients with metastatic malignant melanoma: Proof of principle and early clinical reports from a phase I/IIa trial (2016) (0)
Abstract 2310: With a little help from CD4 T cells in adoptive T-cell transfer (2016) (0)
Session 15: Hodgkin lymphoma 159 GENETIC POLYMORPHISMS INFLUENCE THE RISK OF HODGKIN’S LYMPHOMA (2011) (0)
Ras Peptide Vaccines (1997) (0)
Vaccines targeting key molecules in carcinogenesis (2001) (0)
Abstract 3586: A universal killer T-cell for adoptive cell therapy of cancer (2018) (0)
Intradermal ras peptide vaccination of colorectal cancer patients: a randomized trial of two different dose levels of mutant ras peptides with- or without GM-CSF (2001) (0)
Nucleic acid isolation (1994) (0)
Peptides et fragments de peptides efficaces therapeutiquement (1992) (0)
Process for the preparation of therapeutically useful peptide (1992) (0)
Enhanced expression and anti-tumour activity of T cells engineered to express a cysteine-modified TCR targeting a frameshift mutation in MSI-HI colorectal cancer (2014) (0)
The immunoproteome of pancreatic cancer (2008) (0)
RNA Based Cancer Vaccines - Clinical Trials in Patients with Prostate Cancer and Malignant Melanoma. (2007) (0)
Terapeutiskt anvaendbara like peptides Science peptidfragment. (1992) (0)
Telomerase vaccines: Targeting a "universal" cancer antigen (2001) (0)
hTERT/survivin mRNA-loaded dendritic cell vaccination combined with ex-vivo expanded T cell transfer in stage IV melanoma patients show a longer overall survival in patients with sustained immune responses against hTERT (2014) (0)
Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules. (1994) (0)
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination (2022) (0)
Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients (2013) (0)
From the telomerase derived antigenic peptides (1999) (0)
Antigen presentation and cellular interactions in initiation and regulation of immune responses (1988) (0)
Effects of TGF-β1 on proliferation of cancer stem cells and non-cancer stem cells of lung cancer (2010) (0)
Polypeptides for triggering an immune response against cancer (2001) (0)
Peptides derived from the reading frame shift mutations in TBF II or BAX gene, and pharmaceutical compositions containing these nucleic acid sequences encoding such peptides, plasmids and virusvektoreromfattende slikenukleinsy (1998) (0)
11PD Tapping CD4 T cells for cancer immunotherapy (2016) (0)

This paper list is powered by the following services:

Other Resources About Gustav Gaudernack

en.wikipedia.org

What Schools Are Affiliated With Gustav Gaudernack?

Gustav Gaudernack is affiliated with the following schools: